Canada markets closed

ImmunoPrecise Antibodies Ltd. (IPA.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
5.31-0.17 (-3.10%)
At close: 03:59PM EDT
Currency in CAD

Valuation Measures4

Market Cap (intraday) 129.46M
Enterprise Value 99.29M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)5.56
Price/Book (mrq)2.71
Enterprise Value/Revenue 5.23
Enterprise Value/EBITDA -8.82

Trading Information

Stock Price History

Beta (5Y Monthly) -0.23
52-Week Change 3-32.44%
S&P500 52-Week Change 3-8.83%
52 Week High 320.20
52 Week Low 34.52
50-Day Moving Average 36.46
200-Day Moving Average 36.98

Share Statistics

Avg Vol (3 month) 316.42k
Avg Vol (10 day) 315.11k
Shares Outstanding 523.54M
Implied Shares Outstanding 6N/A
Float 816.17M
% Held by Insiders 15.91%
% Held by Institutions 15.34%
Shares Short (Jun 14, 2022) 412.97k
Short Ratio (Jun 14, 2022) 41.04
Short % of Float (Jun 14, 2022) 4N/A
Short % of Shares Outstanding (Jun 14, 2022) 40.06%
Shares Short (prior month May 12, 2022) 47.62k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Nov 22, 2020
Ex-Dividend Date 4N/A
Last Split Factor 21:5
Last Split Date 3Nov 22, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Apr 29, 2021
Most Recent Quarter (mrq)Jan 30, 2022

Profitability

Profit Margin -89.98%
Operating Margin (ttm)-78.59%

Management Effectiveness

Return on Assets (ttm)-18.66%
Return on Equity (ttm)-42.77%

Income Statement

Revenue (ttm)19M
Revenue Per Share (ttm)0.99
Quarterly Revenue Growth (yoy)6.60%
Gross Profit (ttm)11.4M
EBITDA -14.06M
Net Income Avi to Common (ttm)-17.1M
Diluted EPS (ttm)-0.89
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)32.99M
Total Cash Per Share (mrq)1.7
Total Debt (mrq)2.81M
Total Debt/Equity (mrq)5.90
Current Ratio (mrq)5.68
Book Value Per Share (mrq)2.45

Cash Flow Statement

Operating Cash Flow (ttm)-8.87M
Levered Free Cash Flow (ttm)-4.02M